AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06314412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stoller's Afferent Nerve Stimulation (SANS)
Description: 15 sessions of SANS (5 sessions/week for 3 weeks)
Study NCT04856059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac MRI, ECG/Holter and Blood Biomarkers
Description: Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up
Study NCT05056727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Tablet for oral administration. Unit dose strength: 75, 150 or 300 mg. Dosage level: 75, 150, or 300 mg administered once daily.~The study is designed to use valsartan as the selected ARB therapy adjunct to SZC. However, if an actual shortage of valsartan in a local market jeopardises the ability of participants to enter or continue in the study, valsartan can be temporarily substituted with irbesartan until the shortage of valsartan is resolved.
Study NCT05716776 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography (OCT)
Description: Measurement of retinal nerve fibre layer (RNFL) thickness using optical coherence tomography
Study NCT05090267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Supplement
Description: Participants will take a probiotic supplement or placebo for 90 days.
Study NCT05090267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Vagal Nerve Stimulation (tVNS)
Description: Participants will use a non-invasive stimulator 1 hour daily for 30 days. This stimulator is placed around the ear similar to headphones and produces a very mile electric current. This wellness device is safe to use and painless. Some describe the sensation to be a slight tingle up to a small itch.
Study NCT06180863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azacitidine (CC-486)
Description: Oral azacitidine is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
Study NCT04909138 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DRG stimulation 20 Hz 30/90
Description: Stimulation delivered at 20 Hz and 30 seconds ON, 90 seconds OFF
Study NCT04909138 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DRG stimulation 5 Hz 30/90
Description: Stimulation delivered at 5 Hz and 30 seconds ON, 90 seconds OFF
Study NCT04665362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib
Description: Drug: Recombinant oncolytic virus M1~Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle.~Other name：M1-c6v1~Drug：Anti-PD-1 antibody~Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks.~Other names：SHR-1210, Camrelizumab~Drug: Apatinib~Apatinib is administered orally 250mg once daily.~Other name: Apatinib
Study NCT05200325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational materials for TissueCypher
Description: These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
Study NCT05160571 — intervention group
Intervention type: DEVICE
Intervention: Ion Endoluminal System
Description: Ion Endoluminal Procedure for pulmonary nodule
Study NCT05079594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother voice
Description: Five minutes before the procedure, the mother's voice recording will be played to the baby and the speaker will be placed 30 cm away from the baby. The baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins. Physiological values of the baby will be noted by the researcher 1 minute before the procedure.As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher. After the procedure, the recording will continue to be played until the baby's mother's voice returns to the basal values. Physiological values and comfort levels of the baby will be noted by the researcher 1 minute and 2 minute after the procedure. 2 minutes after the procedure, the baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale.
Study NCT05079594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White noise
Description: Before Operation The decibel meter will be set to an average of 50-60 dB and the speakers will be played at a distance of 30 cm.~Intervention in this group will be made at the elevation. White noise will be played five minutes before the procedure.The baby's comfort level and physiological values will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins.~Order of Operation As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher.~Post-Processing After the procedure, white noise will continue to be listened to until the baby's physiological values return to basal values. Physiological values and baby's comfort level of the baby will be noted by the researcher 1 minute and 2 minute after the heel blood collection is completed.
Study NCT05917860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix is injected subcutaneously into the fatty tissue of the abdomen. A typical protocol consists of a starting dose of 240 mg with a maintenance dose of 80 mg administered every 28 days. In this study, one starting dose and two maintenance doses of Degarelix will be administered between baseline and TULSA treatment in accordance with the terms of Degarelix marketing authorizations.
Study NCT05917860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided transurethral ultrasound ablation (TULSA)
Description: MRI-guided transurethral ultrasound ablation (TULSA) (TULSA-PRO, Profound Medical Inc., Toronto, Canada) will be used to deliver whole-prostate gland treatment in accordance with the terms of TULSA marketing authorizations. The treating physicians will contour the entire prostate gland for a whole gland ablation.
Study NCT05678686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Routine Exercise Group
Description: Exercises (tongue-palate exercises, tongue base exercises, Masako Maneuver, Mendelson Maneuver, Effortful Swallowing, Supraglottic exercises, thermal tactile stimulation) will be performed 2 days a week for 8 weeks, in total 16 sessions and these exercises applied by the physiotherapist.
Study NCT05678686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: PNF Exercise
Description: In addition to the practices in the control group, head-neck PNF(Proprioceptive Neuromuscular Facilitation) movement patterns will be applied to both movement patterns by the physiotherapist using the combined isotonic contraction technique ), 2 days a week for 8 weeks, in total 16 sessions.
Study NCT05678686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: CTAR Exercise
Description: In addition to the practices in the control group, CTAR exercises will be applied in the presence of a physiotherapist, 2 days a week for 8 weeks, a total of 16 sessions. In the CTAR exercise, the patient is asked to flexion and extension the neck by pressing a standard size and inflatable rubber ball placed under his chin against his sternum. Patients will be asked to do the exercise protocol, which consists of isometric and isotonic components.
Study NCT05913869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness Based Stress Reduction
Description: Based on the UMASS curriculum developed by Dr. Jon Kabat-Zinn, it is an 8-week mindfulness stress reduction program. It is a skill-based psychoeducational program that meets 2 hours for 8 weeks to discuss stress, cognition and health. The weekly intervention includes didactic presentations, class dialogue and inquiry, formal (e.g., body scan, walking meditation) and informal (e.g., awareness of pleasant and unpleasant events, interpersonal communications, etc.) mindfulness practice.
Study NCT05913869 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Mindfulness Based Stress Reduction
Description: Based on the UMASS curriculum developed by Dr. Jon Kabat-Zinn, it is an 8-week mindfulness stress reduction program. It is a skill-based psychoeducational program that meets 2 hours for 8 weeks to discuss stress, cognition and health. The weekly intervention includes didactic presentations, class dialogue and inquiry, formal (e.g., body scan, walking meditation) and informal (e.g., awareness of pleasant and unpleasant events, interpersonal communications, etc.) mindfulness practice.
Study NCT05563649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Guided Self-Help-Family-based Treatment
Description: GSH-FBT consists of 10 20-minute sessions for parents only over 9 months. Sessions follow an online curriculum of 65 short videos: 62 with an expert clinician instructing parents on the principles of FBT, and 3 reflections from an adolescent who recovered from AN and completed FBT. Each lecture series contains an introduction orienting the viewer to the videos, 5-9 short videos (\< 7 minutes each), and assigned reading from the parent education manual Help Your Teenager Beat an Eating Disorder. Three lectures include additional resources for parents (e.g., Academy of Eating Disorder (AED) Medical Management Guidelines). Homework assignments are included with some lectures (e.g., strategies to help the child eat during meals, practice making calorically dense meals). In line with GSH approaches, coach-therapists direct parents, to watch or re-watch specific video content contained in the online learning material related to their questions rather than direct behavioral change.
Study NCT05563649 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FBT via Videoconferencing
Description: 15 60-minute sessions of 3-phase manualized FBT modified for videoconferencing will be delivered to participants randomized to this treatment by therapists trained in FBT. The first phase encourages parental management of weight restoration (approximately 8 weekly sessions); the second phase promotes a developmentally appropriate transition back to adolescent management of weight restoration and maintenance under parental supervision (approximately 4 bi-weekly sessions), and the third phase focuses on adolescent development (approximately 3 monthly sessions). Each session consists of 10 minutes with the adolescent individually to discuss progress and the adolescent's perspective on treatment, followed by 50 minutes with the entire family.
Study NCT05256810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-XDH
Description: ALN-XDH administered by SC injection
Study NCT05256810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by SC injection
Study NCT04969276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza High Dose
Description: Sterile suspension for injection in a pre-filled syringe Intramuscular injection
Study NCT04969276 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Inactivated Influenza High Dose
Description: Sterile suspension for injection in a pre-filled syringe Intramuscular injection
Study NCT04969276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine (nucleoside modified)
Description: Sterile suspension (white to off-white) in multidose vial Intramuscular injection
Study NCT04969276 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 mRNA Vaccine (nucleoside modified)
Description: Sterile suspension (white to off-white) in multidose vial Intramuscular injection
Study NCT06547047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed, Agility, and Quickness (SAQ) Training
Description: The SAQ training will include exercises designed to improve speed, agility, and quickness, such as ladder drills, cone drills, sprint drills, and reaction drills.
Study NCT06547047 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular Training
Description: Participants in the control group will follow a standard soccer training regimen, which includes general conditioning exercises, skill drills, and tactical training.
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: i.d. placebo
Description: Participants will receive one i.d. injection of placebo on Day 1
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intranasal H107e
Description: Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 211
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal H107e
Description: Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 211
Study NCT06050356 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal H107e
Description: Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 211
Study NCT05891418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two informational emails with plan information
Description: Informational emails about the benefits of Cost-Sharing Reduction Silver plans.
Study NCT05891418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard notice of eligibility determination
Description: No extra outreach during intervention period.
Study NCT06315764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Following four weeks of treatment (post-1) and additional four weeks of treatment (post-2) the post evaluation was used (post-2).Before and after the foot reflexology, blood pressure was checked twice. Around 20 minutes is spent on foot reflexology .~Each patient in this study did 20 minutes of peddler aerobic training, with the first 5 minutes serving as a warm-up with intensity set at 60 - 65 percent of maximal heart rate, followed by another 10 minutes of peddler training with intensity gradually increased up to 70 - 75 percent, and the last 5 minutes serving as a cooling down with intensity set at 60 - 65 percent of maximal heart rate. After the warm-up and at the end of each training phase, the participants' heart rates were monitored. Finally, if the individual experienced pain, fainting, or shortness of breath, the training was promptly terminated as well as reflexology three times each week for eight weeks
Study NCT05119413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New trio de Kligman
Description: Once daily application in addition to the same sunscreen
Study NCT05119413 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trio Kligman
Description: Once daily application in addition to the same sunscreen
Study NCT05158439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT04961320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Participate in OT session
Study NCT04961320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT05285826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV Vaccine
Description: 9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine administered as a 0.5-mL IM injection
Study NCT05285826 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline solution administered as a 0.5 mL IM injection
Study NCT04789577 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLU-Q-PAN H7N9 Formulation 1
Description: Participants received two doses of the FLU-Q-PAN H7N9 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.
Study NCT04789577 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLU-Q-PAN H7N9 Formulation 2
Description: Participants received two doses of the FLU-Q-PAN H7N9 Formulation 2 vaccine by intramuscular injection in the non-dominant arm.
Study NCT04789577 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLU-Q-PAN H7N9 Formulation 3
Description: Participants received two doses of the FLU-Q-PAN H7N9 Formulation 3 vaccine by intramuscular injection in the non-dominant arm.
Study NCT04789577 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AS03B
Description: Participants received two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.
Study NCT04789577 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AS03A
Description: Participants received two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.
Study NCT04789577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received two doses of Placebo by intramuscular injection in the non-dominant arm.
Study NCT06382389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMONO
Description: Exposure of Emono via facial mask
Study NCT06382389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical air
Description: exposure to Medical Air
Study NCT05092048 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: PHQ-9 and GAD-7 questionnaire
Study NCT05167331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide inhalation
Description: use of Nitrous Oxide inhalation on children's anxiety during a dental treatment
Study NCT05167331 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dispositif de RV - HYPNO VR
Description: use of Virtual Reality on children's anxiety during a dental treatment
Study NCT01239524 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: denervation of thoracodorsal nerve or saving the nerve
Study NCT05475626 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroereisis-
Description: Surgical options include soft tissue procedures, realignment osteotomies and non-fusion motion-limiting techniques.
Study NCT04641702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine challenge
Description: Atropine challenge. After baseline FLIP, subjects will be administered 15 mcg/kg of intravenous atropine. Two minutes after administration, FLIP will be repeated.
Study NCT04641702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal muscle biopsy
Description: Esophageal muscle biopsy. During standard-of-care Heller myotomy or per-oral endoscopic myotomy, 5mm of lower esophageal sphincter and distal esophageal circular muscle will be collected via biopsy forceps.
Study NCT06009289 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light therapy
Description: One hour of exposure to bright light, either by being outdoors or with a phototherapy lamp if indoor
Study NCT06009289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: One hour of exposure to bright light, either by being outdoors or with a phototherapy lamp if indoor
Study NCT05436015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual nature-based intervention
Description: Virtual nature-based intervention is video with Finnish naturepictures and naturesounds shown from a 75 vertical screen monitor
Study NCT05026268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracorporeal anastomosis
Description: intracorporeal stapled side-to-side isoperistaltic anastomosis
Study NCT06142734 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: pyeloplasty
Description: * For laparoscopic pyeloplasty:~* Anaesthesia: general~* Position: a 45-degree lateral decubitus position with the concerned side up. Patient is secured to the operating table. Pneumoperitoneum is adopted through a camera port lateral to the umbilicus~* extra operating ports are created at subcostal and at spinoumbilial line.~* the UPJ is transperitoneally accessed by incising the white line of Toldt and the ipsilateral colon is reflected and the proximal ureter and the pelvis are identified an mobilized~* then Anderson- Hynes pyeloplasty is carried out with insertion of nephroureterostomy or pyeloureterostomy tube.
Study NCT04749355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BST-236
Description: BST-236 is a conjugate of cytarabine and asparagine, provided as a sterile lyophilized powder for IV administration
Study NCT05047978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk protein infant formula
Description: A routine cow's milk-based infant formula
Study NCT05047978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed protein infant formula
Description: A partially hydrolyzed cow's milk protein (PHP) infant formula
Study NCT06201546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block group
Description: TAP block will be administrated after LSG. In TAP block local anesthetic(%0,25 bupivacaine-20ml)will be administrated the between the transversus abdominis muscle and the internal abdominal muscle fascia.
Study NCT06201546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: m-TAPA block group
Description: m-TAPA block will be administrated after LSG. In m-TAPA block local anesthetic (0.25% bupivacaine-20ml) will be administrated between the transversus abdominis muscle and the internal abdominal muscle fascia under the costochondrial region
Study NCT06339294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole Cream
Description: Single time application of clotrimazole ointment was done after aural toilet in external auditory canal via IV catheter